We're a Consulting Group 

We help companies successfully translate their targeting molecules (small molecules, peptides, proteins) into effective radiopharmaceutical therapies.

​

Many organizations excel at engineering high-affinity small molecules, peptides or proteins, but developing a successful radiopharmaceutical requires a distinct set of capabilities—radiochemistry, pharmacology, dosimetry, manufacturing strategy and regulatory planning. Without careful integration of these elements, promising targeting vectors can fail to achieve the biodistribution, safety profile, or operational readiness required for clinical success.

​

Our core focus is enabling therapeutic developers to transform a targeting molecule into a clinically viable radiopharmaceutical. We help teams understand how their vector behaves once radiolabeled, optimize its in-vivo performance, and build development programs that are technically sound, phase-appropriate, and aligned with regulatory and clinical expectations.

​

We integrate seamlessly into the development team—working alongside discovery scientists, translational researchers, CMC leaders, and clinical teams—to provide thoughtful, specific, and actionable guidance. Our role is to identify risks early, resolve technical bottlenecks, and ensure that radiopharmaceutical programs move forward efficiently and predictably.

​

We combine strategic judgment with hands-on execution to guide programs from early feasibility through IND-enabling development. This includes radiochemistry and conjugation strategy, preclinical pharmacology and dosimetry, manufacturing and supply planning.

​

Our experience spans peptides, engineered proteins, antibody fragments, bispecific constructs, and other targeted biologics across oncology. We understand both the scientific and operational realities of converting a promising targeting vector into a safe, effective, and scalable radiopharmaceutical.